BioCryst Pharmaceuticals (BCRX) Competitors $10.07 -0.26 (-2.52%) Closing price 04:00 PM EasternExtended Trading$10.04 -0.03 (-0.30%) As of 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BCRX vs. HALO, RGEN, MDGL, IONS, ALKS, LGND, FOLD, MNKD, CLDX, and DVAXShould you be buying BioCryst Pharmaceuticals stock or one of its competitors? The main competitors of BioCryst Pharmaceuticals include Halozyme Therapeutics (HALO), Repligen (RGEN), Madrigal Pharmaceuticals (MDGL), Ionis Pharmaceuticals (IONS), Alkermes (ALKS), Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), MannKind (MNKD), Celldex Therapeutics (CLDX), and Dynavax Technologies (DVAX). These companies are all part of the "biotechnology" industry. BioCryst Pharmaceuticals vs. Halozyme Therapeutics Repligen Madrigal Pharmaceuticals Ionis Pharmaceuticals Alkermes Ligand Pharmaceuticals Amicus Therapeutics MannKind Celldex Therapeutics Dynavax Technologies Halozyme Therapeutics (NASDAQ:HALO) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, community ranking, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership. Which has better earnings and valuation, HALO or BCRX? Halozyme Therapeutics has higher revenue and earnings than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHalozyme Therapeutics$1.08B6.13$281.59M$3.7614.34BioCryst Pharmaceuticals$503.49M4.18-$226.54M-$0.26-38.67 Does the MarketBeat Community favor HALO or BCRX? Halozyme Therapeutics received 31 more outperform votes than BioCryst Pharmaceuticals when rated by MarketBeat users. Likewise, 69.06% of users gave Halozyme Therapeutics an outperform vote while only 67.12% of users gave BioCryst Pharmaceuticals an outperform vote. CompanyUnderperformOutperformHalozyme TherapeuticsOutperform Votes52969.06% Underperform Votes23730.94% BioCryst PharmaceuticalsOutperform Votes49867.12% Underperform Votes24432.88% Does the media favor HALO or BCRX? In the previous week, Halozyme Therapeutics had 8 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 17 mentions for Halozyme Therapeutics and 9 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 1.04 beat Halozyme Therapeutics' score of 0.48 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Halozyme Therapeutics 10 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral BioCryst Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals believe in HALO or BCRX? 97.8% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. 2.4% of Halozyme Therapeutics shares are owned by company insiders. Comparatively, 4.8% of BioCryst Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more volatility and risk, HALO or BCRX? Halozyme Therapeutics has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Is HALO or BCRX more profitable? Halozyme Therapeutics has a net margin of 43.74% compared to BioCryst Pharmaceuticals' net margin of -30.01%. Halozyme Therapeutics' return on equity of 157.78% beat BioCryst Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Halozyme Therapeutics43.74% 157.78% 25.34% BioCryst Pharmaceuticals -30.01%N/A -24.06% Do analysts recommend HALO or BCRX? Halozyme Therapeutics currently has a consensus target price of $61.90, indicating a potential upside of 14.83%. BioCryst Pharmaceuticals has a consensus target price of $16.56, indicating a potential upside of 64.65%. Given BioCryst Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe BioCryst Pharmaceuticals is more favorable than Halozyme Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Halozyme Therapeutics 2 Sell rating(s) 6 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.17BioCryst Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89 SummaryHalozyme Therapeutics beats BioCryst Pharmaceuticals on 13 of the 18 factors compared between the two stocks. Get BioCryst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCRX vs. The Competition Export to ExcelMetricBioCryst PharmaceuticalsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.10B$2.92B$5.38B$8.42BDividend YieldN/A1.72%5.22%4.11%P/E Ratio-16.4730.7526.6219.77Price / Sales4.18398.55392.02116.56Price / CashN/A168.6838.2534.62Price / Book-4.533.286.814.53Net Income-$226.54M-$72.17M$3.23B$248.18M7 Day Performance2.08%4.23%4.05%1.06%1 Month Performance33.53%7.65%11.64%14.68%1 Year Performance56.62%-28.18%17.11%6.87% BioCryst Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCRXBioCryst Pharmaceuticals4.6145 of 5 stars$10.07-2.5%$16.56+64.4%+68.5%$2.11B$503.49M-16.51530Positive NewsHALOHalozyme Therapeutics4.8622 of 5 stars$66.58+1.1%$63.78-4.2%+18.9%$8.20B$1.08B19.41390RGENRepligen4.791 of 5 stars$133.72+8.5%$173.25+29.6%-25.7%$7.51B$650.43M-262.202,020Positive NewsGap UpMDGLMadrigal Pharmaceuticals4.611 of 5 stars$300.76+2.1%$416.33+38.4%+26.1%$6.68B$317.38M-11.9990Positive NewsIONSIonis Pharmaceuticals4.4285 of 5 stars$33.53+3.9%$56.67+69.0%-11.0%$5.34B$717.25M-11.03800News CoveragePositive NewsAnalyst ForecastALKSAlkermes4.5827 of 5 stars$31.27+3.8%$38.33+22.6%+29.9%$5.16B$1.51B14.412,280Positive NewsLGNDLigand Pharmaceuticals4.3924 of 5 stars$106.38+1.8%$146.14+37.4%+21.1%$2.05B$181.49M42.3880FOLDAmicus Therapeutics4.0127 of 5 stars$6.21+3.8%$16.22+161.2%-32.4%$1.91B$543.14M-34.50480News CoveragePositive NewsHigh Trading VolumeMNKDMannKind2.7862 of 5 stars$4.81+5.5%$10.00+107.9%-7.2%$1.46B$297.60M68.71400CLDXCelldex Therapeutics1.7905 of 5 stars$20.18+10.1%$53.90+167.1%-45.7%$1.34B$7.02M-7.85150Gap UpDVAXDynavax Technologies4.2846 of 5 stars$9.85+4.7%$24.00+143.7%-8.5%$1.18B$294.62M54.72350Positive NewsHigh Trading Volume Related Companies and Tools Related Companies HALO Competitors RGEN Competitors MDGL Competitors IONS Competitors ALKS Competitors LGND Competitors FOLD Competitors MNKD Competitors CLDX Competitors DVAX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCRX) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCryst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioCryst Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BCRX Stock Free BCRX Stock Alerts